Pids

Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update

Retrieved on: 
Monday, January 8, 2024
APDS, PIK3CD, VUS, FDA, Disease, Immunodeficiency, PIK3R1, Laboratory, Euronext Amsterdam, Growth, Patient, Pids, HAE, Pharmaceutical industry

For the full year 2023, total revenues are expected to increase by 19% to approximately US$245 million (preliminary and unaudited*).

Key Points: 
  • For the full year 2023, total revenues are expected to increase by 19% to approximately US$245 million (preliminary and unaudited*).
  • We expect 10% growth in RUCONEST® revenues, significantly exceeding our previous guidance for low single digit annual revenue growth.
  • In 2023, Pharming saw the first full-year, post-pandemic benefit of its first quarter 2020 restructuring and expansion of its U.S. salesforce.
  • Pharming expects to issue full financial results for the fourth quarter and full year 2023 in March 2024.

Frontiers Adopts CCC Ringgold Identify Database as its PID Solution

Retrieved on: 
Tuesday, September 12, 2023
Research, Legal, Technology, Publishing, Security, Communications, Professional Services, Software, Data Management, Science, Metadata, Database, Frontiers, ISO, Article processing charge, ISNI, Open access, ID, APC, CCC, Organization, OA, Acquisition, Pids, PID, Scientific community, Knowledge, Ecosystem, Copyright Clearance Center, Cryptocurrency, Management

CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, today announced Gold Open Access (OA) publisher Frontiers has adopted the industry-leading Ringgold Identify Database as its Persistent Identifier (PID) solution to help power its OA models by normalizing and disambiguating organization data.

Key Points: 
  • CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, today announced Gold Open Access (OA) publisher Frontiers has adopted the industry-leading Ringgold Identify Database as its Persistent Identifier (PID) solution to help power its OA models by normalizing and disambiguating organization data.
  • With over 600,000 Ringgold PIDs and metadata records, the Ringgold Identify Database provides a curated view of organization data to help stakeholders improve data quality, drive strategic decision-making, and support data interoperability across the scholarly communications ecosystem.
  • Used by intermediaries, funders, institutions, and a growing list of leading publishers, the Ringgold Identify Database is the only solution to offer structured organizational hierarchies and consortia connections to help stakeholders quickly understand complex relationships.
  • The Ringgold Identify Database includes rich metadata and additional identifiers, including the ISNI ID, an open ISO standard to support wider interoperability.

Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients

Retrieved on: 
Thursday, July 20, 2023
GRF, Therapy, MCE, Clinical trial, Food and Drug Administration, Ageing, GRFS, SIDS, Patient, Immunodeficiency, Pids, IG, Label, Food, Safety, Medical imaging, Pharmaceutical industry, Vaccine, Grifols

It has demonstrated that patients with primary immunodeficiencies (PIDs) treated with this subcutaneous 20% immunoglobulin (SCIg) product every two weeks achieved non-inferiority in total Ig levels compared with those who received the medication weekly.

Key Points: 
  • It has demonstrated that patients with primary immunodeficiencies (PIDs) treated with this subcutaneous 20% immunoglobulin (SCIg) product every two weeks achieved non-inferiority in total Ig levels compared with those who received the medication weekly.
  • The phase 4 trial also demonstrated similarly good safety and tolerability profiles between biweekly and weekly administration.
  • Results will support the potential product labeling extension of XEMBIFY® to include biweekly dosing, pending review and approval by the United States Food and Drug Administration.
  • “Patients using XEMBIFY® could have an additional dosing option to choose from, providing more convenience and flexibility when controlling their immunodeficiencies,” said Kim Hanna, Grifols Senior Director Clinical Development.

CCC to Host Interactive Webcast on ‘The State of Scholarly Metadata in 2023: Industry Insights From Around the Globe’

Retrieved on: 
Thursday, July 13, 2023
Data Management, Technology, Professional Services, Publishing, Communications, Other Science, Other Technology, Research, Software, Legal, Science, Database, Learning, Metadata, Association of Learned and Professional Society Publishers, Society, Society for Scholarly Publishing, University, Health, SSP, Culture, ISO, University of Vienna, International Association, ISNI, ORCID, Doctor of Philosophy, London, Open access, ID, Government, Information, CCC, OA, FAIR, Acquisition, Pids, STM, Scientific community, Knowledge, APC, Ecosystem, Unilog Content Solutions, Open Access Scholarly Publishing Association, Copyright Clearance Center, Town hall, London Book Fair, VIP, Management, OASPA, Ethics, Access, ALPSP

CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, will present an interactive webcast – The State of Scholarly Metadata in 2023: Industry Insights From Around the Globe – on Thursday, 20 July at 11AM EDT/4 PM BST.

Key Points: 
  • CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, will present an interactive webcast – The State of Scholarly Metadata in 2023: Industry Insights From Around the Globe – on Thursday, 20 July at 11AM EDT/4 PM BST.
  • A VIP panel of industry experts will discuss the importance of prioritizing metadata management for the open scholarly community and explore pragmatic solutions for future publishing workflows.
  • The session is moderated by Deni Auclair , Media Growth Strategies, and Jamie Carmichael , Senior Director, Information and Content Solutions, CCC.
  • “When it comes to moving successful Open Access initiatives forward, high-quality scholarly metadata is crucial,” said Emily Sheahan, Vice President & Managing Director, CCC.

CCC Hosting Panel at The London Book Fair on Reading the Data Compass: The Guiding Role of Metadata in an Increasingly Complex Scholarly Research Ecosystem

Retrieved on: 
Tuesday, April 18, 2023
Software, Research, Entertainment, Books, Data Management, Technology, Other Communications, Publishing, Science, Communications, Other Technology, Other Science, Taylor & Francis, Database, Learning, Association of Learned and Professional Society Publishers, Metadata, Society, Society for Scholarly Publishing, Health, SSP, ISO, International Association, ISNI, London Book Fair, ORCID, Doctor of Philosophy, ID, Open access, Government, CCC, OA, Acquisition, Data, Hearing, Pids, STM, Scientific community, PLOS, Knowledge, APC, Olympia Theatre (New York City), Ecosystem, Open Access Scholarly Publishing Association, Olympia Theatre, Copyright Clearance Center, Environment, Open research, Content, Book, Management, OASPA, ALPSP

CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, is hosting a panel discussion on “Reading the Data Compass: The Guiding Role of Metadata in an Increasingly Complex Scholarly Research Ecosystem” during the Research & Scholarly Publishing Forum at The London Book Fair on 20 April, 11:40 -12:10 in the Olympia Theatre .

Key Points: 
  • CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, is hosting a panel discussion on “Reading the Data Compass: The Guiding Role of Metadata in an Increasingly Complex Scholarly Research Ecosystem” during the Research & Scholarly Publishing Forum at The London Book Fair on 20 April, 11:40 -12:10 in the Olympia Theatre .
  • The database also includes rich metadata and additional identifiers, including the ISNI ID, an ISO Standard open ID to support wider interoperability.
  • CCC is a long-time supporter of the creation, development, and proliferation of identifiers, including supporting initiatives such as ORCID and ISNI .
  • CCC is a member of OASPA (Open Access Scholarly Publishers Association), ALPSP (Association of Learned and Professional Society Publishers), STM (International Association of STM Publishers) and SSP (Society for Scholarly Publishing).

PLOS Adopts CCC Ringgold Identify Database as its PID Solution

Retrieved on: 
Wednesday, February 22, 2023
Software, Research, Networks, Professional Services, Technology, Other Education, Continuing, University, Education, Publishing, Science, Legal, Communications, Russian National Public Library for Science and Technology, CAP, Knowledge, Ecosystem, ID, Metadata, PID, Database, Organization, OA, Open access, APC, Acquisition, ISO, Health, ISNI, Pids, CCC, Scientific community metaphor, Public, Government, PLOS, Northeast Kingdom Community Action, ORCID, Management

CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, today announced The Public Library of Science (PLOS) has adopted the industry-leading Ringgold Identify Database as its Persistent Identifier (PID) solution to streamline organizational data, helping power its Open Access (OA) publishing process with reliability and inclusivity.

Key Points: 
  • CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, today announced The Public Library of Science (PLOS) has adopted the industry-leading Ringgold Identify Database as its Persistent Identifier (PID) solution to streamline organizational data, helping power its Open Access (OA) publishing process with reliability and inclusivity.
  • “Leveraging the Ringgold Identify Database in our publishing workflows helps PLOS better support our authors and reduces operational burdens,” said Randy Townsend, Director, Publishing Operations, PLOS.
  • Used by intermediaries, funders, and a growing list of leading publishers, Ringgold Identify Database is the only solution to offer structured organizational hierarchies and consortia connections to help stakeholders quickly understand complex relationships.
  • For more than ten years, CCC has relied on Ringgold identifiers to disambiguate author affiliations related to APCs managed through RLSC.

Mojio and Mechanic Advisor Unite Platforms to Arm Auto Repair Shops with Real-Time Telematics Data & Automated Marketing for Fleet Customers

Retrieved on: 
Tuesday, November 1, 2022
OEM, T-Mobile, Marketing, TPMS, Software as a service, Service, Trust, GLOBE, Garage, Tire, CRM, Directory, Privacy, OBD-II, Microsoft, Safety, Collection, Maintenance, Pids, Force, Friction, Tire-pressure monitoring system, Communication, Level 1, Machine learning, GPS, Deutsche Telekom, Amazon, Mechanic, Video game, Instrumentation, Online shopping, Taxicab, Audi

The new service, called Steermatics, will be fully integrated within Steer, Mechanic Advisors next-generation CRM for auto repair shops .

Key Points: 
  • The new service, called Steermatics, will be fully integrated within Steer, Mechanic Advisors next-generation CRM for auto repair shops .
  • Together, Mechanic Advisor and Mojio are implementing telematics technologies to change the way a vehicle is serviced, providing greater transparency and safety to the auto repair process, said Mechanic Advisor CEO, Parker Swift.
  • Founded in 2003, Mechanic Advisor has three core products: Steer , a full-service CRM marketing platform, telematics , and a directory for repair shops nationwide.
  • Steer helps repair shops acquire new customers and drives existing customers back to the shop to perform regular maintenance and necessary services.

Spexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model

Retrieved on: 
Thursday, July 7, 2022
Mouse, Tibia, Pathology, Patient, School, Research, DVM, Docetaxel, Biomarker, CXCR4, Degenerative disease, Disease, Immunodeficiency, University of Michigan, Medical school, Neoplasm, University, Spexy Beast, Doctor of Philosophy, Pids, Animal, Prostate cancer, Radiography, Pâ, Program, Tartrate-resistant acid phosphatase, Pharmaceutical industry, Medical imaging, Urology

SPEXIS AG (SIX: SPEX), a clinical-stage biopharmaceutical company, today announced that its CXCR4 inhibitor balixafortide demonstrated synergistic efficacy in combination with docetaxel compared to either drug alone in a metastatic prostate cancer preclinical model.

Key Points: 
  • SPEXIS AG (SIX: SPEX), a clinical-stage biopharmaceutical company, today announced that its CXCR4 inhibitor balixafortide demonstrated synergistic efficacy in combination with docetaxel compared to either drug alone in a metastatic prostate cancer preclinical model.
  • The preclinical study of metastatic prostate cancer combining balixafortide (20mg/kg twice daily in mice, corresponding to a clinically relevant dose) and docetaxel (5mg/kg once weekly) assessed tumor burden and tumor-induced bone degradation.
  • The combination of balixafortide and docetaxel decreased the total tumor burden significantly (p=0.009).
  • These results are encouraging that balixafortide may have significant potential in the treatment of metastatic prostate cancer and other solid tumors.

Spexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model

Retrieved on: 
Thursday, July 7, 2022
Mouse, Tibia, Pathology, Patient, School, Research, DVM, Docetaxel, GLOBE, Biomarker, CXCR4, Degenerative disease, Disease, Immunodeficiency, University of Michigan, Medical school, Neoplasm, University, Spexy Beast, Doctor of Philosophy, Pids, Animal, Prostate cancer, Radiography, Pâ, Program, Tartrate-resistant acid phosphatase, Pharmaceutical industry, Medical imaging, Urology

ALLSCHWIL, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- SPEXIS AG (SIX: SPEX), a clinical-stage biopharmaceutical company, today announced that its CXCR4 inhibitor balixafortide demonstrated synergistic efficacy in combination with docetaxel compared to either drug alone in a metastatic prostate cancer preclinical model.

Key Points: 
  • ALLSCHWIL, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- SPEXIS AG (SIX: SPEX), a clinical-stage biopharmaceutical company, today announced that its CXCR4 inhibitor balixafortide demonstrated synergistic efficacy in combination with docetaxel compared to either drug alone in a metastatic prostate cancer preclinical model.
  • The preclinical study of metastatic prostate cancer combining balixafortide (20mg/kg twice daily in mice, corresponding to a clinically relevant dose) and docetaxel (5mg/kg once weekly) assessed tumor burden and tumor-induced bone degradation.
  • The combination of balixafortide and docetaxel decreased the total tumor burden significantly (p=0.009).
  • These results are encouraging that balixafortide may have significant potential in the treatment of metastatic prostate cancer and other solid tumors.

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, July 1, 2022
SCN, Financial compensation, Patient, Biology, Research, WHIM syndrome, GLOBE, CXCR4, Cancer, B-cell lymphoma, Immunodeficiency, Employment, PID, Immune system, Therapy, Pids, Safety, Medication, Pharmaceutical industry

The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4.

Key Points: 
  • The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4.
  • The inducement awards consist of options to purchase an aggregate of 21,000 shares of X4s common stock.
  • These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4).
  • X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapies for people with immune system dysfunction.